-
Core Evidence
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy
Original Research
(3508) Views (936) Full article downloads
Authors: Giuseppe Derosa, Sibilla Anna Teresa Salvadeo
Published Date February 2008
Volume 2007:2(3) Pages 0 - 0
DOI: http://dx.doi.org/10.2147/CE.S7429
Giuseppe Derosa, Sibilla Anna Teresa Salvadeo
Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
Introduction: Type 2 diabetes mellitus, a metabolic disease with increasing incidence, is one of the most important cardiovascular risk factors. Insulin resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Metformin and the thiazolidinediones, pioglitazone and rosiglitazone, are insulin-sensitizing agents available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of both metformin and pioglitazone in reducing cardiovascular morbidity and mortality. The fixed-dose combination of metformin and pioglitazone appears to be a good option for treating diabetes in insulin-resistant patients.
Aims: The purpose of this article is to review the place in therapy of a fixed-dose combination of pioglitazone and metformin in the management of patients with type 2 diabetes.
Evidence review: The current evidence suggests that combined therapy may help to achieve the recommended goals in the management of diabetes. A fixed-dose formulation of pioglitazone and metformin may provide advantages in terms of glycemic control and other cardiovascular risk factors frequently associated with diabetes.
Place in therapy: The current evidence shows that a fixed-dose formulation of pioglitazone and metformin offers an effective option for the management of patients with type 2 diabetes when monotherapy fails in the achievement of the recommended standards of care.
Key words: cardiovascular risk factors, diabetes, pioglitazone, metformin, outcomes.
Other articles by Professor Giuseppe Derosa
Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
Risk management in the treatment of type 2 diabetes with pioglitazone
Readers of this article also read:
Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis
Corrigendum
Corrigendum
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses
